Revenue segments as reported by the company.

Net product sales

Collaboration revenue

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general, and administrative

Other operating (income) expense, net

Acquired in-process research and development

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Regeneron reports robust Q4 earnings, eyes strategic launches and collaborations

Regeneron Pharmaceuticals showcased strong financial performance and pipeline advancements in Q4 2022.
The company's focus on safety, efficacy, and strategic imperatives positions it for future growth.
Challenges include competitive positioning, trial data anticipation, and managing uncertainties.
Opportunities in market launches, accelerated approvals, and innovative collaborations drive future potential.

Regeneron excels in Q1 with strong revenue growth and pipeline advancements

Regeneron Pharmaceuticals delivered a strong performance in Q1 2023, driven by revenue growth and pipeline advancements in key therapeutic areas like DUPIXENT and EYLEA.
Despite operational challenges in market positioning and regulatory considerations, the company's strengths in research capabilities and strategic planning present growth opportunities.
With a focus on commercialization efforts, expanding indications, and leveraging genetic insights, Regeneron is poised to capitalize on opportunities for sustained success and innovation.
Navigating challenges in market competition and regulatory uncertainties, Regeneron remains proactive in addressing key issues to maintain its position as a leading biopharmaceutical company.

Regeneron reports strong Q2 earnings, eyes aflibercept launch

Regeneron Pharmaceuticals demonstrated strong financial performance and commercial success in Q2 2023.
While facing regulatory challenges, the company remains optimistic about pipeline advancements and potential launches.
Balancing efficacy and safety in treatments, Regeneron aims to capitalize on growth opportunities and strategic partnerships.
Robust cash position and focus on patient well-being position Regeneron for continued success and market expansion.

Regeneron posts robust Q3 results, eyes innovation and market growth

Regeneron's Q3 performance reflects strong revenue growth, financial stability, and promising market potential for key products like Dupixent and EYLEA HD.
While facing legal challenges and competitive pressures, the company's strategic focus on innovation, R&D, and shareholder value management positions it for long-term success.
With a robust pipeline, unique therapeutic targets, and a solid financial foundation, Regeneron is poised for continued growth, market leadership, and innovation in the biopharmaceutical industry.

Regeneron posts strong Q4 results, eyes growth through innovation

Regeneron Pharmaceuticals delivered a strong performance in Q4 2023, driven by successful product launches and financial results in line with expectations.
The company's focus on innovation, strategic leadership, and capital allocation priorities position them well for future growth and market success.
While facing challenges in market dynamics and competition, Regeneron has opportunities to leverage new product approvals and innovative treatment approaches.
Overall, Regeneron's performance highlights their resilience, strategic vision, and commitment to advancing healthcare through groundbreaking therapies.

Regeneron posts solid Q1 results, faces FDA request challenges

Regeneron Pharmaceuticals delivered strong financial performance in Q1 2024, driven by Dupixent and EYLEA HD.
The company's robust pipeline and focus on innovation position it well for future growth.
Challenges include FDA requests for Dupixent efficacy analyses and market entry hurdles for new products.
Opportunities lie in advancing therapies for COPD, severe food allergies, and expanding cancer treatment options.

Regeneron posts robust Q2 earnings, eyes pipeline expansion opportunities

Regeneron Pharmaceuticals demonstrated strong financial performance and product sales growth in Q2.
While facing regulatory challenges, the company's pipeline and market position remain robust.
Opportunities for expansion and innovation present avenues for future growth.
Overall, Regeneron's Q2 results reflect resilience and strategic focus.

Regeneron Pharmaceuticals reports strong Q3 results and eyes innovative growth

Regeneron's Q3 performance reflects solid revenue and earnings growth driven by key products. While facing regulatory challenges and capital allocation decisions, the company's focus on innovation and strategic investments positions it well for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Regeneron (REGN) beats on Q4 earnings and sales on solid performance of Dupixent, Eylea and incremental contribution from oncology drug, Libtayo.

Regeneron (REGN) Q4 Earnings, Sales Beat on Solid Dupixent Show

The big biotech was firing on all cylinders, and getting strong growth out of its top-selling products.

What's Behind Regeneron's Stellar Q4 Update

The shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) are up 2.3% to trade at $510.38 this morning, after the company reported better-than-expected fourth-quarter earnings of $9.53 per share -- significantly higher than Wall Street's estimates of $8.39 per share -- as well as a revenue beat.

Blowout Earnings, Revenue Beat Push Regeneron Stock Higher

Regeneron Pharmaceuticals posted fourth-quarter earnings that smashed Wall Street expectations, helped by sales of its eczema drug.

Regeneron Earnings Crushed Estimates

Regeneron (REGN) delivered earnings and revenue surprises of 14.54% and 1.45%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Regeneron (REGN) Beats Q4 Earnings and Revenue Estimates

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) reported fourth-quarter earnings of $9.53 per share, which beat the analyst consensus estimate of $8.39. Quarterly sales of $2.42 billion increased 30% year-on-year, which was in line with expectations.

Regeneron's Q4 Double-Digit Top and Bottom-Line Growth Propelled By Higher Sales From Eylea And Dupixent

Shares of Regeneron Pharmaceuticals Inc. gained 3.2% in premarket trading on Friday after the company said its COVID-19 antibody cocktail treatment generated $145.5 million in sales in the fourth quarter of 2020 as part of its earnings. The treatment, which received emergency use authorization in the U.S. in November, generated $185.7 million in sales for the full year.

Regeneron's COVID-19 antibody drug generated $145 million in sales in Q4

Regeneron earnings easily beat Q4 views, while sales growth was in line with estimates. Regeneron stock rose early Friday.

Regeneron Earnings Easily Beat; REGN Stock Rises

Shares of Regeneron Pharmaceuticals (NASDAQ:REGN) moved higher by 2.7% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share were up 27.07% year over year to $9.53, which beat the estimate of $8.39.

Regeneron Pharmaceuticals: Q4 Earnings Insights

Shares of Regeneron Pharmaceuticals Inc. jumped 3.0% in premarket trading Friday, after the biotechnology company reported a fourth-quarter profit that rose well above expectations, while revenue was in line with forecasts. Net income increased to $1.15 billion, or $10.24 a share, from $792.0 million, or $6.93 a share, in the year-ago period.

Regeneron's stock rallies after profit rises well above expectations, while revenue matches

TARRYTOWN, N.Y., Feb. 5, 2021 /PRNewswire/ -- Fourth quarter 2020 revenues increased 30% to $2.42 billion versus fourth quarter 2019(4) Fourth quarter 2020 EYLEA® U.S. net sales increased 10% to $1.34 billion versus fourth quarter 2019 and full year 2020 EYLEA U.S. net sales increased 7%...

Regeneron Reports Fourth Quarter and Full Year 2020 Financial and Operating Results

On Friday, February 05, Regeneron Pharmaceuticals (NASDAQ:REGN) will release its latest earnings report. Benzinga's outlook for Regeneron Pharmaceuticals is included in the following report.

Regeneron Pharmaceuticals's Earnings Outlook

Disney

NIKE

Peloton

Roku

Block

Vroom

Investing in stocks that show long-term potential is a tried and true way to earn some long-term gains. Here's a look at seven growth stocks worth buying this year.

7 Safe Growth Stocks to Put In Your Buy-and-Hold Portfolio

Investors are likely to focus on the performance of Eylea and Dupixent along with other pipeline updates when Regeneron (REGN) reports fourth-quarter 2020 results.

Will Eylea, Dupixent Drive Regeneron's (REGN) Q4 Earnings?

Amgen

Biogen

Gilead Sciences

Merck

Pfizer

AbbVie

Alexion Pharma

Bristol-Myers

Earnings season is in full swing, and we have put together a preview of some of the world's largest players in the health care sector reporting this coming week.

Amgen, Biogen, Gilead, Merck, Pfizer, and More Health Care Earnings Coming This Week

Eli Lilly

There's some good news and some bad news.

Can Eli Lilly and Regeneron Antibody Treatments Beat New COVID Strains?

Regeneron (REGN) reports research data confirming that antibody REGEN-COV is effective against the SARS-CoV-2 variants.

Regeneron (REGN) COVID-19 Cocktail Effective Against New Variants

Strong interim trial data boosts the prospects for a treatment already worth billions.

Could This Drug Be 100% Effective in Preventing Symptomatic COVID-19 Infections?

Roku and Regeneron are poised to be top-notch growth picks.

2 High-Growth Stocks Ready to Soar in 2021

Regeneron (REGN) reports positive initial results from a phase III study evaluating REGEN-COV antibody cocktail as a passive vaccine for the prevention of people at high risk of COVID-19 infection.

Regeneron (REGN) Reports Positive Data on Cocktail for COVID-19

Shares of Regeneron Pharmaceuticals Inc. gained 1.2% in premarket trading on Wednesday after the company said its COVID-19 antibody cocktail still works against two new more infectious strains of the virus: the B.1.1.7 and the B.1.351. The company worked with researchers at Columbia University to assess how the drug, which has received emergency authorization in the U.S., works against the new strains in a laboratory, according to a preprint published Wednesday.

Regeneron says its COVID-19 antibody cocktail still works against new strains in lab test

TARRYTOWN, N.Y., Jan. 27, 2021 /PRNewswire/ -- Columbia University researchers and Regeneron have independently confirmed findings; data included in bioRxiv paper and submitted for peer-reviewed publication Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that researchers in...

REGEN-COV™ Antibody Cocktail Is Active Against SARS-CoV-2 Variants First Identified in the UK and South Africa

Eli Lilly is back with another round of promising data on its Covid-19 antibody therapies.

Eli Lilly and Regeneron Report More Positive Data on Covid-19 Antibody Cocktails

Regeneron's (REGN) efforts to expand the label of its approved drugs and concurrently develop the pipeline are impressive and position it for growth in 2021.

Regeneron's (REGN) Performance Strong in 2020: What Lies Ahead?

Shares of Regeneron Pharmaceuticals Inc. were up 1.8% in premarket trading on Tuesday after the company said its COVID-19 antibody cocktail can prevent people at high risk of a COVID-19 infection from contracting the virus. These are the initial results from an ongoing Phase 3 clinical trial for what Regeneron calls a "passive vaccine.

News for Regeneron Pharmaceuticals Stock (REGN)